CervoMed Inc.

CRVO Healthcare Biotechnology

CervoMed Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, down 58.9% from fiscal 2024.

Revenue
−99.6%
EPS
+8.57%
Free cash flow
−6.20%

Quarter to June 2026, against a year earlier

1.41 0.04 −2.76%
Market cap
$21.9M
P/E
0.0×
Fwd P/E
−0.7×
Dividend yield
—
F-score
2/9
Altman Z
0.28
Beneish M
−4.94
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Piotroski F-Score
2 — — — — — — — — —
P/E ratio
0.00 0.00 0.00 — — — — — — —
Altman Z-Score
0.28 0.55 (3.93) — — — — — — —
P/S ratio
17.83 1.94 7.06 — — — — — — —
Altman Z″-Score (non-manufacturers)
(12.90) 8.38 (15.23) — — — — — — —
P/FCF ratio
0.00 0.00 0.00 — — — — — — —
P/Operating CF
(10.86) (2.35) (19.86) — — — — — — —
Beneish M-Score
(4.94) (1.18) — — — — — — — —
P/B ratio
3.92 0.48 6.83 — — — — — — —
EV/Sales
15.86 (0.73) 7.78 — — — — — — —
EV/EBITDA
0.00 0.39 0.00 — — — — — — —
EV/FCF
(2.66) 0.42 (7.05) — — — — — — —
Current Ratio
4.91 11.11 3.84 5.61 12.92 7.71 8.51 11.09 3.59 0.36
Net Debt/EBITDA
0.74 2.14 1.00 (2.39) 1.52 1.16 1.23 0.67 0.74 (0.05)
Debt/Equity
0.00 0.00 0.00 (1.38) 0.00 0.00 0.01 0.00 0.03 0.26
ROE
(93.92%) (69.95%) 16.77% (713.60%) (80.69%) (71.80%) (66.02%) (144.53%) (17.21%) (394.54%)
ROA
(81.77%) (61.41%) (30.74%) (27.64%) (73.50%) (62.25%) (55.77%) (120.07%) (12.00%) (182.55%)
ROIC
0.00% (4,064.19%) 0.00% 0.00% 0.00% (157.62%) (118.50%) (155.49%) (55.05%) (114.12%)
Return on Tangible Assets
(147.98%) (41.56%) (29.47%) (169.87%) (69.05%) (97.85%) (89.52%) (314.68%) (35.19%) 654.71%
Average Days of Receivables
38.90 84.49 46.76 — — — — — — —
Earnings Yield
(37.72%) (86.75%) (43.85%) — — — — — — —
Free Cash Flow Yield
(33.44%) (89.82%) (15.65%) — — — — — — —
Free Cash Flow per Share
(2.59) (2.05) (2.80) (4.97) (11.17) (18.88) (110.27) (249.37) (1,161.84) (1,183.58)
Book value per Share
2.02 4.86 2.77 (17.37) 26.89 34.57 225.22 361.38 1,929.99 1,009.31
Free Cash Flow
(23.45) (16.53) (7.45) (2.57) (14.50) (13.55) (9.86) (10.77) (12.78) (10.77)
EV/EBIT
0.00 0.39 0.00 — — — — — — —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026